Global Plasminogen Market Strategic Research Report

Scope of the Report

The global Plasminogen market size is predicted to grow from US$ 16.44 million in 2025 to US$ 158 million in 2032; it is expected to grow at a CAGR of 38.6% from 2026 to 2032.

Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF). The complete amino acid sequence contains 790 amino acids. Native plasminogen (glu-plasminogen) has a N-terminal glutamic acid group. Partial plasma proteolysis gives rise to a molecule with N-terminal lysine (lysplasminogen). Currently, the product has obtained the designation of orphan drug by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). In 2021, U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a disorder that can impair normal tissue and organ function and may lead to blindness. The report mainly targeting the research status, predicted competitive landscape, market potential and future trends of plasminogen market.

The plasminogen market is primarily driven by its critical role in fibrinolysis and thrombolytic therapy, where it is used to dissolve blood clots and treat related conditions such as deep vein thrombosis, pulmonary embolism, and myocardial infarction. As the prevalence of cardiovascular diseases and clotting disorders continues to rise globally, demand for plasminogen-based therapies is growing steadily. Additionally, the use of plasminogen in rare diseases such as plasminogen deficiency, which can cause severe tissue damage and vision loss, further strengthens the market’s importance in specialized treatment areas.

Beyond therapeutic applications, the plasminogen market is also supported by research activities focused on wound healing, tissue repair, and ocular health. Biopharmaceutical advancements and innovative drug delivery systems are expanding the scope of plasminogen-based products. However, the market faces challenges such as the high cost of therapies, limited availability of plasma-derived products, and stringent regulatory approval processes. Despite these hurdles, ongoing clinical trials and growing awareness of fibrinolytic agents are expected to create new opportunities for expansion in the coming years.

This report presents a comprehensive overview of the global Plasminogen market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Intravenous Injection
• Eye Drops

Segment by players, this report covers

• Kedrion(Prometic)

Segment by Application

• Ligneous Conjunctivitis
• Diabetic Foot
• Wound Healing
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Plasminogen market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Ligneous Conjunctivitis, Diabetic Foot, Wound Healing evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact